Hemodynamic effect of oral TA-064 after dobutamine in congestive heart failure.
The hemodynamic effect of oral TA-064 (20 mg), a newly synthesized inotropic agent, was compared with that of intravenous dobutamine (5 micrograms/kg/min) in eight patients with congestive heart failure who had been treated with intravenous dobutamine, digitalis, diuretics, and prazosin. Hemodynamics was measured using a Swan-Ganz catheter during the pre-dobutamine control period, during dobutamine infusion period, during the pre-TA-064 control period and at 90 minutes after oral administration of TA-064. Stroke work index was increased and mean pulmonary capillary wedge pressure was decreased with TA-064 or dobutamine. Cardiac index and stroke index was increased by each drug, and pulmonary and systemic vascular resistances were decreased. Mean systemic arterial pressure, heart rate and pressure-rate product did not significantly change in comparison with the control level. In conclusion, TA-064 has a hemodynamic effect similar to that of dobutamine and may be useful as an oral substitute for dobutamine in patients with congestive heart failure after temporary management with dobutamine.
Takatsu
Y
Y
Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
Yui
Y
Y
Hattori
R
R
Sakaguchi
K
K
Susawa
T
T
Yui
N
N
Kawai
C
C
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002303:Cardiac Output, Low / Q000188:drug therapy / Q000503:physiopathology; D002316:Cardiotonic Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004280:Dobutamine / Q000008:administration & dosage*; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D002316:Cardiotonic Agents; D004983:Ethanolamines; D004280:Dobutamine; C037293:denopamine